Thomas Bohnacker

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović et al. · Journal of Medicinal Chemistry · 2017 · 132 citations · Full text

Chemoprevention Strategy, Immunology, Clinical Candidate +19

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

Romina Marone, Dominik Erhart, Ann C. Mertz et al. · Molecular Cancer Research · 2009 · 124 citations

Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

Thomas Bohnacker, A.E. Prota, Florent Beaufils et al. · Nature Communications · 2017 · 113 citations · Full text

Ras is an indispensable coregulator of the class I _B phosphoinositide 3-kinase p87/p110γ

Barbara Kurig, Aliaksei Shymanets, Thomas Bohnacker et al. · Proceedings of the National Academy of Sciences · 2009 · 95 citations · Full text

Immunology, Molecular Biology, Inflammation +22

PI3Kγ Adaptor Subunits Define Coupling to Degranulation and Cell Motility by Distinct PtdIns(3,4,5)P ₃ Pools in Mast Cells

Thomas Bohnacker, Romina Marone, Emilie Collmann et al. · Science Signaling · 2009 · 90 citations